Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Phase 1
18+
2 sites in MI, NY
What this study is about
This Phase 1 study is focused on people with advanced solid tumors. The primary outcome being measured is Part 1 Dose Escalation and Part 2 Dose Refinement: Number of Participants with Adverse Events (AEs).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part 1 Dose Escalation and Part 2 Dose Refinement: Number of Participants with Adverse Events (AEs), Part 3 Expansion: Objective Response Rate (ORR)
Secondary: Part 1 Dose Escalation and Part 2 Dose Refinement: Disease Control Rate (DCR), Part 1 Dose Escalation and Part 2 Dose Refinement: Duration Of Response (DOR), Part 1 Dose Escalation and Part 2 Dose Refinement: Maximum Concentration (Cmax) of GEN1079, Part 1 Dose Escalation and Part 2 Dose Refinement: ORR, Part 1 Dose Escalation and Part 2 Dose Refinement: Time to Cmax (Tmax) of GEN1079, Part 3 Expansion: Cmax of GEN1079, Part 3 Expansion: DCR, Part 3 Expansion: DOR